Abstract

Neuroblastoma is the most common pediatric solid tumor of neural crest origin. The current treatment options for neuroblastoma produce severe side effects. Programmed death-ligand 1 (PD-L1), chronic inflammation, and non-coding RNAs are known to play a significant role in the pathogenesis of neuroblastoma. Cancer cells and the surrounding cells in the tumor microenvironment express PD-L1. Programmed death-1 (PD-1) is a co-receptor expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. Chronic inflammation is involved in the recruitment of leukocytes, production of cytokines and chemokines that in turn, lead to survival, metastasis, and angiogenesis in neuroblastoma tumors. The miRNAs and long non-coding (lnc) RNAs have emerged as a novel class of non-coding RNAs that can regulate neuroblastoma associated cell-signaling pathways. The dysregulation of PD-1/PD-L1, inflammatory pathways, lncRNAs, and miRNAs have been reported in clinical and experimental samples of neuroblastoma. These signaling molecules are currently being evaluated for their potential as the biomarker and therapeutic targets in the management of neuroblastoma. A monoclonal antibody called dinutuximab (Unituxin) that attaches to a carbohydrate molecule GD2, on the surface of many neuroblastoma cells, is being used as an immunotherapy drug for neuroblastoma treatment. Atezolizumab (Tecentriq), an engineered monoclonal antibody against PD-L1, are currently in clinical trial for neuroblastoma patients. The lncRNA/miRNA-based therapeutics is being developed to deliver tumor suppressor lncRNAs/miRNAs or silencing of oncogenic lncRNAs/miRNAs. The focus of this review is to discuss the current knowledge on the immune checkpoint molecules, PD-1/PD-L1 signaling, inflammation, and non-coding RNAs in neuroblastoma.

Original languageEnglish (US)
Pages (from-to)53-65
Number of pages13
JournalSeminars in Cancer Biology
Volume52
DOIs
StatePublished - Oct 2018

Fingerprint

Untranslated RNA
Neuroblastoma
Ligands
Inflammation
Long Noncoding RNA
MicroRNAs
Monoclonal Antibodies
Neoplasms
Tumor Microenvironment
Therapeutics
Chemokines
Immunotherapy
Immune System
Leukocytes
Biomarkers
Carbohydrates
Clinical Trials
Pediatrics
Cytokines
Neoplasm Metastasis

Keywords

  • Immuno-therapy
  • Inflammation
  • Neuroblastoma
  • Non-coding RNAs
  • PD-L1

ASJC Scopus subject areas

  • Cancer Research

Cite this

PD-L1, inflammation, non-coding RNAs, and neuroblastoma : Immuno-oncology perspective. / Nallasamy, Palanisamy; Chava, Srinivas; Verma, Sumit S.; Mishra, Shruti; Gorantla, Santhi; Coulter, Donald W; Byrareddy, Siddappa Nagadenahalli; Batra, Surinder Kumar; Gupta, Subash C.; Challagundla, Kishore B.

In: Seminars in Cancer Biology, Vol. 52, 10.2018, p. 53-65.

Research output: Contribution to journalReview article

@article{fbfe325f31cd4043ba3d38c88ba2cc18,
title = "PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective",
abstract = "Neuroblastoma is the most common pediatric solid tumor of neural crest origin. The current treatment options for neuroblastoma produce severe side effects. Programmed death-ligand 1 (PD-L1), chronic inflammation, and non-coding RNAs are known to play a significant role in the pathogenesis of neuroblastoma. Cancer cells and the surrounding cells in the tumor microenvironment express PD-L1. Programmed death-1 (PD-1) is a co-receptor expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. Chronic inflammation is involved in the recruitment of leukocytes, production of cytokines and chemokines that in turn, lead to survival, metastasis, and angiogenesis in neuroblastoma tumors. The miRNAs and long non-coding (lnc) RNAs have emerged as a novel class of non-coding RNAs that can regulate neuroblastoma associated cell-signaling pathways. The dysregulation of PD-1/PD-L1, inflammatory pathways, lncRNAs, and miRNAs have been reported in clinical and experimental samples of neuroblastoma. These signaling molecules are currently being evaluated for their potential as the biomarker and therapeutic targets in the management of neuroblastoma. A monoclonal antibody called dinutuximab (Unituxin) that attaches to a carbohydrate molecule GD2, on the surface of many neuroblastoma cells, is being used as an immunotherapy drug for neuroblastoma treatment. Atezolizumab (Tecentriq), an engineered monoclonal antibody against PD-L1, are currently in clinical trial for neuroblastoma patients. The lncRNA/miRNA-based therapeutics is being developed to deliver tumor suppressor lncRNAs/miRNAs or silencing of oncogenic lncRNAs/miRNAs. The focus of this review is to discuss the current knowledge on the immune checkpoint molecules, PD-1/PD-L1 signaling, inflammation, and non-coding RNAs in neuroblastoma.",
keywords = "Immuno-therapy, Inflammation, Neuroblastoma, Non-coding RNAs, PD-L1",
author = "Palanisamy Nallasamy and Srinivas Chava and Verma, {Sumit S.} and Shruti Mishra and Santhi Gorantla and Coulter, {Donald W} and Byrareddy, {Siddappa Nagadenahalli} and Batra, {Surinder Kumar} and Gupta, {Subash C.} and Challagundla, {Kishore B}",
year = "2018",
month = "10",
doi = "10.1016/j.semcancer.2017.11.009",
language = "English (US)",
volume = "52",
pages = "53--65",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - PD-L1, inflammation, non-coding RNAs, and neuroblastoma

T2 - Immuno-oncology perspective

AU - Nallasamy, Palanisamy

AU - Chava, Srinivas

AU - Verma, Sumit S.

AU - Mishra, Shruti

AU - Gorantla, Santhi

AU - Coulter, Donald W

AU - Byrareddy, Siddappa Nagadenahalli

AU - Batra, Surinder Kumar

AU - Gupta, Subash C.

AU - Challagundla, Kishore B

PY - 2018/10

Y1 - 2018/10

N2 - Neuroblastoma is the most common pediatric solid tumor of neural crest origin. The current treatment options for neuroblastoma produce severe side effects. Programmed death-ligand 1 (PD-L1), chronic inflammation, and non-coding RNAs are known to play a significant role in the pathogenesis of neuroblastoma. Cancer cells and the surrounding cells in the tumor microenvironment express PD-L1. Programmed death-1 (PD-1) is a co-receptor expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. Chronic inflammation is involved in the recruitment of leukocytes, production of cytokines and chemokines that in turn, lead to survival, metastasis, and angiogenesis in neuroblastoma tumors. The miRNAs and long non-coding (lnc) RNAs have emerged as a novel class of non-coding RNAs that can regulate neuroblastoma associated cell-signaling pathways. The dysregulation of PD-1/PD-L1, inflammatory pathways, lncRNAs, and miRNAs have been reported in clinical and experimental samples of neuroblastoma. These signaling molecules are currently being evaluated for their potential as the biomarker and therapeutic targets in the management of neuroblastoma. A monoclonal antibody called dinutuximab (Unituxin) that attaches to a carbohydrate molecule GD2, on the surface of many neuroblastoma cells, is being used as an immunotherapy drug for neuroblastoma treatment. Atezolizumab (Tecentriq), an engineered monoclonal antibody against PD-L1, are currently in clinical trial for neuroblastoma patients. The lncRNA/miRNA-based therapeutics is being developed to deliver tumor suppressor lncRNAs/miRNAs or silencing of oncogenic lncRNAs/miRNAs. The focus of this review is to discuss the current knowledge on the immune checkpoint molecules, PD-1/PD-L1 signaling, inflammation, and non-coding RNAs in neuroblastoma.

AB - Neuroblastoma is the most common pediatric solid tumor of neural crest origin. The current treatment options for neuroblastoma produce severe side effects. Programmed death-ligand 1 (PD-L1), chronic inflammation, and non-coding RNAs are known to play a significant role in the pathogenesis of neuroblastoma. Cancer cells and the surrounding cells in the tumor microenvironment express PD-L1. Programmed death-1 (PD-1) is a co-receptor expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. Chronic inflammation is involved in the recruitment of leukocytes, production of cytokines and chemokines that in turn, lead to survival, metastasis, and angiogenesis in neuroblastoma tumors. The miRNAs and long non-coding (lnc) RNAs have emerged as a novel class of non-coding RNAs that can regulate neuroblastoma associated cell-signaling pathways. The dysregulation of PD-1/PD-L1, inflammatory pathways, lncRNAs, and miRNAs have been reported in clinical and experimental samples of neuroblastoma. These signaling molecules are currently being evaluated for their potential as the biomarker and therapeutic targets in the management of neuroblastoma. A monoclonal antibody called dinutuximab (Unituxin) that attaches to a carbohydrate molecule GD2, on the surface of many neuroblastoma cells, is being used as an immunotherapy drug for neuroblastoma treatment. Atezolizumab (Tecentriq), an engineered monoclonal antibody against PD-L1, are currently in clinical trial for neuroblastoma patients. The lncRNA/miRNA-based therapeutics is being developed to deliver tumor suppressor lncRNAs/miRNAs or silencing of oncogenic lncRNAs/miRNAs. The focus of this review is to discuss the current knowledge on the immune checkpoint molecules, PD-1/PD-L1 signaling, inflammation, and non-coding RNAs in neuroblastoma.

KW - Immuno-therapy

KW - Inflammation

KW - Neuroblastoma

KW - Non-coding RNAs

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85036622340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036622340&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2017.11.009

DO - 10.1016/j.semcancer.2017.11.009

M3 - Review article

C2 - 29196189

AN - SCOPUS:85036622340

VL - 52

SP - 53

EP - 65

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -